Novartis Vanrafia Phase III data support slowing of kidney function decline in patients with IgA nephropathy
Basel, February 13, 2026 – Novartis today announced final results from the…
Alimentaria+Hostelco strengthens its international leadership with a 41% increase in global offerings
BARCELONA, Spain, Dec. 2, 2025 /PRNewswire/ -- Alimentaria+Hostelco, the leading international platform…
Kia Announces November 2025 Global Sales Results
November 2025 global sales of 262,065 units, down 0.8% Y/yIn Korea, Kia…
Interim Report January September 2025
Interim Report January – September 2025 Third Quarter 2025 (compared to third…
Fruit Attraction 2025 Strengthens Its Global Leadership with a Record 121,137 Trade Professionals
MADRID, Oct. 20, 2025 /PRNewswire/ -- Fruit Attraction 2025, organised by IFEMA…
The 138th Canton Fair Opens with Emphasis on Innovation, Intelligence, and Sustainability
GUANGZHOU, China, Oct. 17, 2025 /PRNewswire/ -- On October 15, the 138th China…
Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant…
Rezolve Ai Gains Powerful Institutional Backing as Market Undervaluation Becomes Clear
Citadel, BlackRock, Vanguard, Jane Street, Northern Trust, Man Group, and State Street…
Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism
September 06, 2025 14:30 ET | Source: BridgeBio Pharma, Inc. - 80%…
Medidata Secures a Leader Position in Everest Group’s PEAK Matrix Assessment for eCOA, Driving the New Patient Experience Forward
Medidata eCOA was the highest Leader recognized in the evaluation, supporting over…